Extracorporeal membrane oxygenation 2001: The odyssey continues

Clinics in Perinatology

Volumn 28, Issue 3, 2001, Pages 629-653

  Schumacher, Robert E ^a   Baumgart, Stephen ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; NITRIC OXIDE;

CLINICAL TRIAL; CONGENITAL DIAPHRAGM HERNIA; COST EFFECTIVENESS ANALYSIS; EXTRACORPOREAL OXYGENATION; FOLLOW UP; HANDICAPPED CHILD; HEALTH CARE COST; HIGH FREQUENCY VENTILATION; HUMAN; LIQUID VENTILATION; MECONIUM ASPIRATION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NERVOUS SYSTEM DEVELOPMENT; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; TREATMENT OUTCOME;

EID: 0034834206     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(05)70110-X     Document Type: Article

References (57)

1. One- to three-year outcome for 14 neonatal survivors of extracorporeal membrane oxygenation
2. American Academy of Pediatrics Committee on Fetus and Newborn: Recommendations on extracorporeal membrane oxygenation
3. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure: The Neonatal Inhaled Nitric Oxide Study Group
4. Inhaled nitric oxide in term and near-term infants: Neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS)
5. Report of the NIH workshop on diffusion of ECMO technology
6. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation
7. Surfactant treatment of full-term newborns with respiratory failure
8. Extracorporeal membrane oxygenation (ECMO) in neonatal respiratory failure: 100 Cases
9. Extracorporeal circulation in neonatal respiratory failure: A prospective randomized study
10. Diagnosis-related criteria in the consideration of extracorporeal membrane oxygenation in newborns previously treated with highfrequency jet ventilation
11. Respiratory function in survivors of the United Kingdom extracorporeal membrane oxygenation trial
12. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn: Clinical Inhaled Nitric Oxide Research Group
13. Prospective, randomized comparison of high-frequency oscillation and conventional ventilation in candidates for extracorporeal membrane oxygenation
14. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: A randomized, double-masked, placebo-controlled, dose-response, multicenter study
15. Surfactant replacement therapy for meconium aspiration syndrome
16. Artificial surfactant therapy in hyaline-membrane disease
17. A matched pairs analysis of venoarterial and venovenous extracorporeal life support in neonatal respiratory failure
18. Morbidity for survivors of extracorporeal membrane oxygenation: Neurodevelopmental outcome at 1 year of age
19. Neurodevelopmental status at age five years of newborns treated with extracorporeal membrane oxygenation
20. Clinical antecedents of neurologic and audiologic abnormalities in survivors of neonatal extracorporeal membrane oxygenation
21. Partial liquid ventilation in critically ill infants receiving extracorporeal life support: Philadelphia Liquid Ventilation Consortium
22. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): How new treatment modalities have affected ECMO utilization
23. Ten years of extracorporeal membrane oxygenation: Neurodevelopmental outcome
24. A cost-effectiveness analysis of the application of nitric oxide versus oxygen gas for near-term newborns with respiratory failure: Results from a Canadian randomized clinical trial
25. Long-term pulmonary function in children treated for meconium aspiration syndrome with extracorporeal life support
26. Pathophysiology of congenital diaphragmatic hernia. VIII: Inhaled nitric oxide requires exogenous surfactant therapy in the lamb model of congenital diaphragmatic hernia
27. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn
28. Adverse neurodevelopmental outcome after extracorporeal membrane oxygenation among newborns with bronchopulmonary dysplasia
29. Risk factors for bronchopulmonary dysplasia after extracorporeal membrane oxygenation
30. The early evaluation of survivors after extracorporeal membrane oxygenation for neonatal pulmonary failure
31. Extracorporeal membrane oxygenation and the ethics of clinical research in pediatrics
32. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome: The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group
33. Long-term neurophysiologic outcome after neonatal extracorporeal membrane oxygenation
34. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure: Survanta in Term Infants Study Group
35. Extracorporeal membrane oxygenation and conventional medical therapy in newborns with persistent pulmonary hypertension of the newborn: A prospective randomized study
36. The effect of extracorporeal membrane oxygenation on the survival of newborns with high-risk congenital diaphragmatic hernia: 45 cases from a single institution
37. Surfactant decreases pulmonary vascular resistance and increases pulmonary blood flow in the fetal lamb model of congenital diaphragmatic hernia
38. Principles and practice of venovenous extracorporeal membrane oxygenation
39. Neurodevelopmental outcome in ECMO vs near-miss ECMO patients at 5 years of age
40. Percutaneous access for venovenous extracorporeal life support in newborns
41. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn: The Inhaled Nitric Oxide Study Group
42. Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial
43. Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension
44. The changing demographics of neonatal extracorporeal membrane oxygenation patients reported to the extracorporeal life support organization (ELSO) registry
45. Extracorporeal membrane oxygenation: Will this therapy continue to be as efficacious in the future?
46. Follow-up of infants treated with extracorporeal membrane oxygenation for newborn respiratory failure
47. Extracorporeal membrane oxygenation in term newborns: A prospective cost-benefit analysis
48. Extracorporeal membrane oxygenator therapy
49. Ventilatory response to combined high frequency jet ventilation and conventional mechanical ventilation for the rescue treatment of severe neonatal lung disease
50. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome
51. Surfactant inhibition in experimental meconium aspiration
52. National experience with extracorporeal membrane oxygenation for newborn respiratory failure: Data from 715 cases
53. Long-term follow-up of infants and children treated with extracorporeal membrane oxygenation (ECMO): A preliminary report
54. Severe respiratory failure in newborns: Mortality and morbidity rates and neurodevelopmental outcomes
55. ECMO in evolution: The impact of changing patient demographics and alternative therapies on ECMO